TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Matrix Medical Network Announces Sale of Decentralized Clinical Trials Service Line to Emvenio Research

Tuesday, August 09, 2022

Matrix Medical Network® (Matrix) and Emvenio Research® (Emvenio) today announced the sale of the Matrix Clinical Trials service line to Emvenio, a leading decentralized clinical trials (DCT) company. The transaction will provide Emvenio with proven DCT capabilities, while allowing Matrix to focus on improving the health and wellness of health plan members, and keeping America's workers productive and safe, through its design of custom and flexible clinical solutions. Post transaction, Emvenio will deploy additional resources, technology, and capital to continue to grow and scale its clinical trials services both domestically and internationally, making clinical research more accessible, equitable, and effective.

"At the onset of the pandemic Matrix mobilized quickly to provide decentralized clinical trial solutions in support of vaccine and therapy development for COVID-19. We leveraged our skilled clinicians, Mobile Health Clinics, and experienced leaders to adapt traditional clinical trials protocols to better reach and recruit diverse, underserved, and high-risk patients," said Catherine J. Tabaka, Matrix Chief Executive Officer. "We are incredibly proud of the remarkable work the Matrix Clinical Trials team started during the pandemic and continued to expand upon. I am excited about this transition and look forward to watching the leaders and employees of Emvenio continue to develop and deliver decentralized clinical trial solutions that best serve those patients who most need access to new treatments."

"The leaders of Matrix Clinical Trials showed leadership, agility, creativity, and perseverance in building a decentralized clinical trial organization from the ground up," said Keith Henthorne, Emvenio Chief Executive Officer. "I look forward to working closely with these leaders in order to build upon this solid foundation established by Matrix and to continue making clinical trials more accessible to diverse populations throughout the world. To ensure continued access to clinical trials for the patients who need it most, many Matrix employees and leaders will be a part of the Emvenio team going forward. I am proud to be working alongside strong leaders like Dr. Daniel Castillo and Thad Wolfram, amongst others, and look forward to growing the company with them."

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit